While the clinical significance of the p.Thr519Met variant remains inconclusive, prior studies have implicated other CHEK2 mutations in the pathogenesis of breast, colorectal, and thyroid cancers. The gene discussed is CHEK2; the disease is thyroid gland carcinoma.